hit counter
Aclaris Therapeutics, Inc. (ACRS) Stock News Sentiment & Price - Sentifly
ACRS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aclaris Therapeutics, Inc. (ACRS)

USA
Biotechnology
NASDAQ
ACRS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ACRS Latest news
GlobeNewsWire
Neutral
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
2021-08-27 16:01

WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the “Settlement Hearing”) will be held on November 30, 2021 at 11:00 a.m. ET, before the Honorable Lewis J. Liman at the U.S. District Court for the Southern District of New York, 500 Pearl Street, New York, NY 10007 (the “Court”) in the matter of In re Aclaris Therapeutics, Inc. Derivative Litigation, Lead Case No. 1:19-cv-10641-LJL (the “Consolidated Derivative Action”).

GlobeNewsWire
Neutral
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
2021-08-26 16:01

WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor conferences:

Zacks Investment Research
Positive
Should You Buy Aclaris Therapeutics (ACRS) Ahead of Earnings?
2021-08-05 12:10

Aclaris Therapeutics (ACRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire
Neutral
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
2021-08-05 07:00

WAYNE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2021 and provided a corporate update.

Zacks Investment Research
Positive
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
2021-07-30 16:43

Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

24/7 Wall Street
Neutral
Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More
2021-06-15 09:11

Tuesday's futures were fairly positive after a somewhat mixed start to the week.

GlobeNewsWire
Neutral
Aclaris Announces Pricing of Public Offering of Common Stock
2021-06-09 19:55

WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares of its common stock at a price to the public of $17.75 per share.  In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 1,056,338 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters' option. The offering is expected to close on or about June 14, 2021, subject to customary closing conditions.

Zacks Investment Research
Positive
Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
2021-06-09 12:01

Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.

GlobeNewsWire
Neutral
Aclaris Announces Proposed Public Offering of Common Stock
2021-06-08 16:15

WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions, $75 million in shares of its common stock in an underwritten public offering.  All of the shares of common stock to be sold in the offering will be offered by Aclaris. Aclaris also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Pulse2
Negative
RMED, HOOK, JZXN, ACRS, OPRA, CVAC Stock Prices Fall Intraday
2021-06-08 14:41

The stock prices of RMED, HOOK, JZXN, ACRS, OPRA, and CVAC have fallen noticeably today. These are the details.

Loading more news...